Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor signaling pathway. [GOC:TermGenie]
Positive regulation of vascular endothelial growth factor (VEGF) signaling pathway is a complex process that involves the coordinated action of multiple signaling molecules and cellular components. It plays a crucial role in various physiological processes, including angiogenesis (formation of new blood vessels), vasculogenesis (development of the vascular system), and wound healing.
**Key Steps in Positive Regulation of VEGF Signaling:**
1. **VEGF Binding and Receptor Activation:** The process begins with VEGF binding to its specific receptors, VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1). These receptors are tyrosine kinase receptors, meaning they have intrinsic enzymatic activity to phosphorylate other proteins. Binding of VEGF to VEGFR2 is particularly crucial for downstream signaling.
2. **Receptor Dimerization and Autophosphorylation:** Upon VEGF binding, VEGFR2 receptors dimerize (pair up), triggering a series of autophosphorylation events. This means the receptor itself adds phosphate groups to specific tyrosine residues on its cytoplasmic domain.
3. **Recruitment of Adaptor Proteins:** Phosphorylated tyrosine residues on VEGFR2 serve as docking sites for adaptor proteins, such as Shc and Grb2. These adaptors link the receptor to downstream signaling cascades.
4. **Activation of the Ras-MAPK Pathway:** The adaptor protein Grb2 recruits SOS, a guanine nucleotide exchange factor (GEF), which activates Ras, a small GTPase. Activated Ras triggers a cascade of protein kinases, including Raf, MEK, and ERK (the mitogen-activated protein kinase). This pathway promotes cell survival, proliferation, and migration.
5. **Activation of the PI3K-Akt Pathway:** Phosphorylated VEGFR2 also activates phosphatidylinositol 3-kinase (PI3K). PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits and activates Akt (protein kinase B). Akt promotes cell survival and angiogenesis by inhibiting apoptosis (programmed cell death) and stimulating protein synthesis.
6. **Regulation of Transcription:** Activated ERK and Akt pathways ultimately converge on transcription factors, such as nuclear factor-kappa B (NF-κB), which control the expression of genes involved in angiogenesis, cell growth, and migration.
7. **Formation of New Blood Vessels:** The activated signaling pathways lead to the formation of new blood vessels through a process called angiogenesis. This process involves sprouting of new capillaries from existing blood vessels, driven by VEGF and other angiogenic factors.
**Regulation of VEGF Signaling:**
The positive regulation of VEGF signaling is tightly controlled by a variety of mechanisms:
* **Ligand Availability:** VEGF production is regulated by various factors, including hypoxia (low oxygen levels), growth factors, and cytokines.
* **Receptor Expression:** The expression of VEGFRs can be modulated by cellular context and environmental cues.
* **Negative Regulators:** Several proteins, including Sprouty, thrombospondin-1, and endoglin, inhibit VEGF signaling.
* **Endocytosis and Degradation:** VEGFRs are internalized and degraded via endocytosis, limiting signal duration.
**Dysregulation of VEGF Signaling:**
Abnormal regulation of VEGF signaling is implicated in various pathological conditions, including:
* **Cancer:** VEGF signaling promotes tumor growth and metastasis by stimulating angiogenesis and vascular permeability.
* **Diabetic Retinopathy:** Excessive VEGF production contributes to the development of abnormal blood vessels in the retina, leading to vision loss.
* **Macular Degeneration:** Increased VEGF levels contribute to the formation of abnormal blood vessels in the macula, affecting central vision.
* **Arthritis:** VEGF signaling is involved in inflammation and joint damage in arthritis.
Understanding the detailed mechanisms of positive regulation of VEGF signaling is crucial for developing novel therapeutic strategies targeting angiogenesis and related diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Vascular endothelial growth factor A | A vascular endothelial growth factor A, long form that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15692] | Homo sapiens (human) |
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
4-phenylphenol | 4-phenylphenol: RN given refers to cpd without isomeric designation biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4. | hydroxybiphenyls | |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
4-phenylbenzoic acid | 4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd | ||
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
proanthocyanidin a1 | procyanidin A1: from aqueous extract of peanut skin; structure in first source | flavonoid oligomer | |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source | ||
phosphomannopentaose sulfate | phosphomannopentaose sulfate: structure in first source |